Clinical Trials
200 trialsMAHOGANY
BeOne Medicines
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
OLYMPIA-1
Regeneron Pharmaceuticals
CAN3001
Janssen Research & Development, LLC
OLYMPIA-5
Regeneron Pharmaceuticals
EPCOREâ„¢FL-2
Genmab
Celestimo
Hoffmann-La Roche
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Sinocelltech Ltd.
NETTER-3
Novartis
SYMPHONY-1
Ipsen
LIBERTY
Swedish Orphan Biovitrum
LEDA
Novartis
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
SIGMA
Nuvation Bio Inc.
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
EVANTHEA
Alzheimer's Prevention and Reversal Project, Inc.
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Memorial Sloan Kettering Cancer Center
OLYMPIA-2
Regeneron Pharmaceuticals
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Novartis
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
InMIND
Incyte Corporation
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
ZUMA-22
Gilead Sciences
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Alliance for Clinical Trials in Oncology
RELEVANCE
The Lymphoma Academic Research Organisation
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
EPCORE FL-1
Genmab
MAGNIFY
Celgene
SELENE
Janssen Research & Development, LLC
RELEVANCE
Celgene
PACIFICO
University of Liverpool
STRONGER
The George Institute
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Beijing Mabworks Biotech Co., Ltd.
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
MorningLyte
The Lymphoma Academic Research Organisation
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
PUMICE
Beijing Tiantan Hospital
ILyAD
University of Rochester
2002
Xenikos
MAINTAIN
University of Giessen
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
ADVANCE
Amgen
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
University College, London
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group